Friday, 31 May 2013

A novel therapy for the most common form of lung cancer shows promise and seems to yield largely manageable side effects, according to new research that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology. The researchers, from Fox Chase Cancer Center, are conducting an ongoing clinical trial to determine whether the compound is more effective at treating tumors than existing treatments. Hossein Borghaei, DOs, chief of thoracic medical oncology at Fox Chase, said: "We're very excited about this drug...


Post a Comment


Powered by Blogger.

ads 3

Popular Posts

ads 4

ads 5